FierceBiotech Names Yumanity Therapeutics As One of Its "Fierce 15" Biotech Companies of 2015

FierceBiotech Names Yumanity Therapeutics As One of Its "Fierce 15" Biotech Companies of 2015

Cambridge, Mass. – September 30, 2015Yumanity Therapeutics, a company focused on transforming drug discovery for diseases caused by protein misfolding, today announced that it has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. 

Launched in December 2014 by Tony Coles, M.D. and Susan Lindquist, Ph.D., Yumanity seeks to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The company's initial focus is neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). The company's proprietary platforms have already identified one potential new target for treating Parkinson's disease, and the team is advancing its new chemical lead series for this condition, as well as identifying additional compounds for Parkinson's disease, Alzheimer's disease and ALS.

"We are honored to be named to the 2015 Fierce 15 and believe this is a testament to the potential of our approach to transform drug discovery for neurodegenerative diseases caused by protein misfolding," said Dr. Coles, chairman and chief executive officer of Yumanity.

It is estimated that more than 55 million people worldwide suffer from neurodegenerative diseases, with no currently approved disease-modifying therapies available.1-3 As modern therapeutic interventions increase life expectancy, the number of patients suffering from these diseases is expected to double every 20 years.1-2 Global costs for treating these diseases are currently estimated at $818 billion and expected to grow to more than $1 trillion by 2030.1-3

About The Fierce 15

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's thirteenth annual Fierce 15 selection. A complete list of "Fierce 15" companies can be found online at www.fiercebiotech.com/fierce15. 

An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.

About Yumanity Therapeutics

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Formed in 2014 by renowned biotech industry leader, Tony Coles, M.D., and protein folding science pioneer, Susan Lindquist, Ph.D., the company is initially focused on discovering disease-modifying therapies for patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Leveraging its three integrated platforms, Yumanity's innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. For more information, please visit yumanity.com.

###

CONTACTS:

Yumanity Therapeutics

Dan Budwick,

Pure Communications

(973) 271-6085

[email protected]

FierceBiotech

Rebecca Friend

202-824-5050

[email protected]

 

  1. UBS, Alzheimer's Report, July 2014; Industry Research.
  2. Alzheimer's Disease International, World Alzheimer Report 2015
  3. Parkinson's Disease Foundation. http://www.pdf.org/en/parkinson_statistics

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.